TGTX TG Therapeutics Inc.

TG Therapeutics to Present at Upcoming Investor Conferences

TG Therapeutics to Present at Upcoming Investor Conferences

NEW YORK, May 27, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its participation at three upcoming virtual investor conferences. Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, is scheduled to participate in the following:

  • Jefferies Virtual Healthcare Conference: Fireside chat scheduled to take place on Tuesday, June 1, 2021, at 2:00 PM ET
  • Goldman Sachs 42nd Annual Global Healthcare Conference: Fireside chat scheduled to take place on Tuesday, June 8, 2021, at 1:20 PM ET
  • Raymond James Human Health Innovation Conference: Presentation scheduled to take place on Tuesday, June 22, 2021, at 10:00 AM ET

A live webcast of each presentation will be available on the Events page, located within the Investors & Media section, of the Company’s website at . Following each event, an archive file will be available for thirty days.

ABOUT TG THERAPEUTICS, INC.

TG Therapeutics is a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. In addition to an active research pipeline including five investigational medicines across these therapeutic areas, TG has received accelerated approval from the U.S. FDA for UKONIQ® (umbralisib), for the treatment of adult patients with relapsed/refractory marginal zone lymphoma who have received at least one prior anti-CD20-based regimen and relapsed/refractory follicular lymphoma who have received at least three prior lines of systemic therapies. Currently, the Company has three programs in Phase 3 development for the treatment of patients with relapsing forms of multiple sclerosis (RMS) and patients with chronic lymphocytic leukemia (CLL) and several investigational medicines in Phase 1 clinical development. For more information, visit , and follow us on Twitter  and .



UKONIQ® is a registered trademark of TG Therapeutics, Inc.



CONTACT:

 Investor Relations
 Email:
 Telephone: 1.877.575.TGTX (8489), Option 4
  
 Media Relations:
 Email:
 Telephone: 1.877.575.TGTX (8489), Option 6

 



EN
27/05/2021

Underlying

TGTXTG Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TG Therapeutics Inc.

 PRESS RELEASE
Free
TGTX TG Therapeutics...

TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Re...

TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance Fourth quarter and full year 2025 total revenue of $192.6 million and $616.3 million, including BRIUMVI U.S. net revenue of $182.7 million and $594.1 million, respectively Target guidance of approximately $875-900 million in total global revenue for 2026 Conference call to be held today, Thursday, February 26, 2026, at 8:30 AM ET NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its f...

February 26, 2026 1 EN
 PRESS RELEASE
Free
TGTX TG Therapeutics...

TG Therapeutics to Host Conference Call on Fourth Quarter and Full Yea...

TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call to be Held Thursday, February 26, 2026, at 8:30 am ET NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Thursday, February 26, 2026, at 8:30 AM ET to discuss results for the fourth quarter and full year 2025 and to provide a business outlook for 2026. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, ...

February 23, 2026 1 EN
 PRESS RELEASE
Free
TGTX TG Therapeutics...

Long Term Data Published in JAMA Neurology Demonstrate Sustained Effic...

Long Term Data Published in JAMA Neurology Demonstrate Sustained Efficacy and Consistent Safety of BRIUMVI in Relapsing Multiple Sclerosis During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient treatment Overall safety profile of BRIUMVI remained consistent over 5 years of continuous treatment, with no new safety signals emerging with prolonged treatment NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the publication of long term/five-year data from the...

February 17, 2026 1 EN
 PRESS RELEASE
Free
TGTX TG Therapeutics...

TG Therapeutics Announces Collaboration with Christina Applegate to Ra...

TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis Campaign debuted during Super Bowl LX and introduced , a new platform designed to create space for honest conversation among people living with MS NEW YORK, Feb. 08, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced a collaboration with actress Christina Applegate to help raise awareness of multiple sclerosis (MS) and support meaningful conversations for those living with the disease. Christina Applegate, who has been living with MS for 5 years, will...

February 8, 2026 1 EN
 PRESS RELEASE
Free
TGTX TG Therapeutics...

TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituxim...

TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy), to be presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held in San Diego, California. Links to each presentation are included below. Michael S. Weiss, Chief Executive Officer an...

February 6, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch